BANGALORE, INDIA -- (Marketwired) -- 09/13/13 --
Biocon Ltd, Asia's largest biotech company, and CytoSorbents Corporation (OTCQB: CTSO), based in the United States, announced today, World Sepsis Day, that they have entered into a strategic partnership with an initial distribution agreement for India and select emerging markets, under which Biocon will have the exclusive commercialization rights for CytoSorb®, a novel therapy for the management of sepsis.
CytoSorb® is a safe and effective extracorporeal cytokine filter, designed to target the prevention or treatment of organ failure which is the cause of nearly half of all deaths in the intensive care unit. If left unchecked, 'cytokine storm' caused by excessive cytokine production can cause massive inflammation, organ failure and death in common life-threatening conditions such as sepsis, burn injury, trauma, lung injury, and pancreatitis. CytoSorb® has CE Mark regulatory approval, and is clinically proven to control cytokine storm in critically-ill patients by reducing key cytokines in blood by 30-50%. It also works easily with standard dialysis machines used in hospitals.
Biocon and CytoSorbents will initially focus on the treatment of sepsis -- the end result of an excessive immune response to infection. The effective treatment of sepsis needs to address two components -- the infection and the over-activation of the immune system. By combining Biocon's critical care antibiotics to treat the infection that are also compatible with CytoSorb® therapy to modulate the immune response, the two companies will be providing the most comprehensive solution for sepsis management in the market.
Kiran Mazumdar Shaw, Chairperson & Managing Director, Biocon Ltd, said, "We believe our partnership with CytoSorbents will enable us to address the huge unmet need of sepsis management in India and emerging markets. CytoSorb® is a 'first-in-class' therapy that can provide an effective solution to physicians to treat critically ill patients suffering from sepsis. This move reflects our commitment to bring differentiated products to India that will help address various healthcare challenges faced by millions of patients in our country."
Rakesh Bamzai, President Marketing, Biocon Ltd, expressed: "CytoSorb® is a safe and well-tolerated innovative therapy for managing cytokine storm in critically ill patients. Very high levels of cytokines are known to cause multiple organ failure, which is often life threatening. Through CytoSorb®, we offer a promising treatment option to high risk patients in their fight against sepsis and other critical illnesses. We are confident that this will be a revolutionary tool for critical care specialists in sepsis treatment."